MarginsXMarginsX
Home › Markets › Health Care › OLMA

Olema Oncology Inc. (OLMA)

OLMA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.36
-2.65% on the day
Market cap
$644.8M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerOLMA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001750284
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
3.2 months
$47.5M cash at September 30, 2026
Share count, 1 year
+27.6%
2025-11-06 to 2026-11-05 · +60.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
-$24.7M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term."
10-Q 2026-11-10
Cash and burn$47.5M cash; operating cash flow -$44.3M a quarter.Report 2026-09-30
Shares outstanding87,606,263 (2026-11-05); 68,659,923 a year earlier; 54,769,800 three years earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-11-19
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $24.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$73.6M-$47.1M$47.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$63.2M-$45.9M$48.6MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q1 2026
2026-03-31
Not filed-$53.1M-$46.0M$52.5MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2025
2025-12-31
Not filed-$46.1M-$38.3M$48.3MNo debt tagsNeeds four quarters10-K 2026-03-16
Q3 2025
2025-09-30
Not filed-$42.2M-$34.5M$35.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$43.8M-$29.9M$52.5MNo debt tagsNeeds four quarters10-Q 2026-08-10
Q1 2025
2025-03-31
Not filed-$30.4M-$44.0M$50.6MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2024
2024-12-31
Not filed-$33.6M-$26.3M$139.5MNo debt tagsNeeds four quarters10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-12-11
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 566 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.1%
1 month+7.7%
3 months-28.1%
Year to date-69.8%
1 year-4.8%
From 52-week high-78.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
DSGNDesign Therapeutics Inc.$9.92-5.25%$635.2M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
IMMXImmix Biopharma Inc.$7.48-4.59%$626.9M
ALMSAlumis Inc.$5.14-8.21%$667.3M
JANXJanux Therapeutics Inc.$10.92-3.96%$668.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier